Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CORTEXYME, INC.

(CRTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Health Care Stocks Drifting Lower This Afternoon

10/27/2021 | 01:38pm EST


ę MT Newswires 2021
All news about CORTEXYME, INC.
11/23Cortexyme to Present at 4th Annual Evercore ISI HealthCONx Conference on November 30th
BU
11/11Cortexyme Says Trial Shows Atuzaginstat Slowed Cognitive Decline in Patients With Alzhe..
MT
11/11Cortexyme's Atuzaginstat Slowed Cognitive Decline in Alzheimer's Patients and P. Gingiv..
MT
11/11Cortexyme CTAD 2021 Readout Roundtable Presentation
PU
11/11CORTEXYME'S ATUZAGINSTAT SLOWED COGN : Additional Top-line Data Presented at CTAD 2021
BU
11/11Citigroup Adjusts Cortexyme's Price Target to $2 From $5, Maintains Sell Rating
MT
11/04Cortexyme to Present Additional Top-line GAIN Trial Results and Analysis at CTAD 2021 o..
BU
11/04Cortexyme to Present Additional Top-Line Gain Trial Results and Analysis at CTAD 2021 o..
CI
11/04SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors Cortexym..
PR
10/29CORTEXYME, INC. Management's Discussion and Analysis of Financial Condition and Result..
AQ
More news
Analyst Recommendations on CORTEXYME, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -89,2 M - -
Net cash 2021 98,0 M - -
P/E ratio 2021 -4,91x
Yield 2021 -
Capitalization 421 M 421 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 38
Free-Float 67,0%
Chart CORTEXYME, INC.
Duration : Period :
Cortexyme, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CORTEXYME, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 6
Last Close Price 14,08 $
Average target price 38,50 $
Spread / Average Target 173%
EPS Revisions
Managers and Directors
Casey Crawford Lynch Chairman, President & Chief Executive Officer
Christopher P. Lowe Chief Operating & Financial Officer
Stephen S. Dominy Chief Scientific Officer & Director
Michael J. Detke Chief Medical Officer
Leslie J. Holsinger Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CORTEXYME, INC.-49.93%421
MODERNA, INC.188.59%122 239
LONZA GROUP AG25.98%57 878
IQVIA HOLDINGS INC.46.64%50 192
SEAGEN INC.-9.40%29 014
CELLTRION, INC.-40.67%24 745